SRR13780272
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- MYOGENESIS+0.330
- G2M_CHECKPOINT+0.320
- PANCREAS_BETA_CELLS+0.290
- DNA_REPAIR+0.230
- HEDGEHOG_SIGNALING+0.220
- OXIDATIVE_PHOSPHORYLATION+0.160
- MITOTIC_SPINDLE+0.150
- GLYCOLYSIS+0.130
- MYC_TARGETS_V1+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.560
- TNFA_SIGNALING_VIA_NFKB-0.540
- ALLOGRAFT_REJECTION-0.530
- IL6_JAK_STAT3_SIGNALING-0.520
- INFLAMMATORY_RESPONSE-0.460
- ANGIOGENESIS-0.410
- IL2_STAT5_SIGNALING-0.390
- ANDROGEN_RESPONSE-0.380
- COMPLEMENT-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.862 |
| 2 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.860 |
| 3 | BS_AWH9757B | high-grade glioma | — | 0.855 |
| 4 | BS_FEV5A0HN | high-grade glioma | — | 0.850 |
| 5 | sclc2008_S40.txt | — | cohortSC | 0.849 |
| 6 | BS_WH5HDE0A | medulloblastoma | — | 0.844 |
| 7 | SRR8518262 | — | E | 0.844 |
| 8 | SRR13780268 | — | cohortSC | 0.835 |
| 9 | C3N-02283 | — | cohortMD1 | 0.834 |
| 10 | TCGA-D8-A13Y-01A-11R-A115-07 | — | B | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |